stephenrosenman Oct. 22 at 1:34 PM @YazzJr They have been talking to GSK and PFE for some time now. Not sure about AZn ReplyShareLike
stephenrosenman Oct. 22 at 11:09 AM @BESKST I'm not convinced that Anchor gets thumbs down. I have to believe with SPA and circus of Adcom that negotiation of label is in order ReplyShareLike
framus_morrigan Oct. 22 at 7:03 AM @stephenrosenman @ckbike oh man, not a liberty to say who .... but you say who! ReplyShareLike
stephenrosenman Oct. 22 at 6:26 AM @ckbike The FDA panel webcast. Not at liberty to say who. Title is: Sr. VP Regulatory Affairs ReplyShareLike
ckbike Oct. 22 at 6:06 AM @stephenrosenman Who's this sr. regulatory figure and which webcast are you referencing? ReplyShareLike
ckbike Oct. 22 at 6:06 AM @stephenrosenman Who' ReplyShareLike
stephenrosenman Oct. 22 at 6:05 AM $AMRN Interesting conversation with sr. regulatory figure on webcast - says doctor comments and questions nullify 9-2 vote impact greatly ReplyShareLike